Last updated on March 2018

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Brief description of study

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Detailed Study Description

Safety: Treatment-Emergent AE; Treatment-Related AE, SAE and Clinical significant AE; Dose Limiting Toxicities (DLT). PK: Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time of Maximum concentration observed (Tmax). Efficacy: Overall Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) and Duration of Response.

Clinical Study Identifier: NCT02567656

Contact Investigators or Research Sites near you

Start Over

Jasmine Zain

City of Hope
Duarte, CA United States

Bradley Haverkos

University of Colorado Cancer Center
Aurora, CO United States

Yasuhiro Oki, MD

MD Anderson Cancer Center
Houston, TX United States

Lauren Pinter-Brown

Chao Family Comprehensive Cancer Center University of California Irvine
Orange, CA United States

Mary Jo Lechowicz

Emory University School of Medicine
Atlanta, GA United States

Sumana Devata

University of Michigan Comprehensive Cancer Center
Ann Arbor, MI United States

Rod Ramchandren

Karmanos Cancer Institute
Detroit, MI United States

Neil Korman

University Hospitals Cleveland Medical Center
Cleveland, OH United States